TY - JOUR
T1 - Author Correction
T2 - Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care (Nature Reviews Clinical Oncology, (2025), 22, 5, (327-347), 10.1038/s41571-025-01013-1)
AU - Mansouri, Alireza
AU - Ozair, Ahmad
AU - Bhanja, Debarati
AU - Wilding, Hannah
AU - Mashiach, Elad
AU - Haque, Waqas
AU - Mikolajewicz, Nicholas
AU - de Macedo Filho, Leonardo
AU - Mahase, Sean S.
AU - Machtay, Mitchell
AU - Metellus, Philippe
AU - Dhermain, Frédéric
AU - Sheehan, Jason
AU - Kondziolka, Douglas
AU - Lunsford, L. Dade
AU - Niranjan, Ajay
AU - Minniti, Giuseppe
AU - Li, Jing
AU - Kalkanis, Steven N.
AU - Wen, Patrick Y.
AU - Kotecha, Rupesh
AU - McDermott, Michael W.
AU - Bettegowda, Chetan
AU - Woodworth, Graeme F.
AU - Brown, Paul D.
AU - Sahgal, Arjun
AU - Ahluwalia, Manmeet S.
N1 - Publisher Copyright:
© Springer Nature Limited 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Correction to: Nature Reviews Clinical Oncologyhttps://doi.org/10.1038/s41571-025-01013-1, published online 19 March 2025. In the version of the article initially published, in the second paragraph of the “Mitigating iatrogenic seeding of brain parenchyma and leptomeninges” section, two percentages were switched in the sentence “..the LMD development rate at 2 years was 16.6% among 114 patients who underwent neoadjuvant SRS (n = 114) versus 3.2% in 66 patients who received adjuvant SRS”. This text has now been corrected to read “..the LMD development rate at 2 years was 3.2% among 114 patients who underwent neoadjuvant SRS versus 16.6% in 66 patients who received adjuvant SRS” in the HTML and PDF versions of the article.
AB - Correction to: Nature Reviews Clinical Oncologyhttps://doi.org/10.1038/s41571-025-01013-1, published online 19 March 2025. In the version of the article initially published, in the second paragraph of the “Mitigating iatrogenic seeding of brain parenchyma and leptomeninges” section, two percentages were switched in the sentence “..the LMD development rate at 2 years was 16.6% among 114 patients who underwent neoadjuvant SRS (n = 114) versus 3.2% in 66 patients who received adjuvant SRS”. This text has now been corrected to read “..the LMD development rate at 2 years was 3.2% among 114 patients who underwent neoadjuvant SRS versus 16.6% in 66 patients who received adjuvant SRS” in the HTML and PDF versions of the article.
UR - https://www.scopus.com/pages/publications/105018183084
UR - https://www.scopus.com/pages/publications/105018183084#tab=citedBy
U2 - 10.1038/s41571-025-01083-1
DO - 10.1038/s41571-025-01083-1
M3 - Comment/debate
C2 - 41044428
AN - SCOPUS:105018183084
SN - 1759-4774
VL - 22
SP - 996
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 12
ER -